Research
Research Alert: Danaher Reports Solid Q1 2026 Results, Highlights Strategic Masimo Acquisition
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:DHR reported strong Q1 2026 results with adjusted EPS of $2.06 vs. consensus of $1.94 (+9.5% Y/Y), while revenue of $5.951B (+3.5% Y/Y) came slightly below consensus of $5.993B. The biotechnology segment continued as the primary growth driver with 7.0% Y/Y core revenue growth, fueled by sustained bioprocessing momentum, offsetting a 4.0% Y/Y core decline in Diagnostics due to lighter respiratory season. Management raised the high end of 2026 EPS guidance to $8.35-$8.55 and maintained full-year core revenue growth guidance of 3%-6% Y/Y. The company recently announced its intention to acquire Masimo Corporation for $9.9B, a leading pulse oximetry and patient monitoring provider. We think this acquisition could be one of the largest medtech M&A deals of 2026 and significantly expand DHR's diagnostics portfolio. In our view, the company's diversified portfolio and operational excellence through the Danaher Business System continue to position it well to navigate market headwinds while driving productivity gains.
$DHR